Jie He

Dr. Jie He

Chongqing Medical University, Chongqing, China
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
HYHuan Yang
Huan Yang
XZXuemei Zhang
Xuemei Zhang
YDYu-Bin Ding
Yu-Bin Ding
HXhui xiong
hui xiong
SXShaojian Xiang
Shaojian Xiang
HQHongbo Qi
Hongbo Qi
Preeclampsia is a leading contributor to increased maternal morbidity and mortality in the perinatal period. Increasing evidence demonstrates that ferroptosis is an essential mechanism for the pathogenesis of preeclampsia. Elabela is a novel small-molecule polypeptide, mainly expressed in embryonic and transplacental tissues, with an ability to promote cell proliferation and invasion. However, its specific regulatory mechanism in preeclampsia has not been completely elucidated. In this study, we first reveal an increased grade of ferroptosis accompanied by a downregulation of the expression of Elabela in preeclampsia placentas. We then confirm the presence of a ferroptosis phenotype in the placenta of the mouse PE-like model, and Elabela can reduce ferroptosis in the placenta and improve adverse pregnancy outcomes. Furthermore, we demonstrate that targeting Elabela alleviates the cellular dysfunction mediated by Erastin promoting increased lipid peroxidation in vitro. Subsequent mechanistic studies suggest that Elabela increases FTH1 levels by inhibiting the ferritinophagy pathway, and consequently chelates the intracellular labile iron pool and eventually arrests ferroptosis. In conclusion, Elabela deficiency exacerbates ferroptosis in the placenta, which is among the potential mechanisms in the pathogenesis of preeclampsia. Targeting the Elabela–ferritinophagy–ferroptosis signaling axis provides a new therapeutic intervention strategy to alleviate preeclampsia.

15 July 2021 in ACS Applied Electronic Materials
Verified
Journal Article
Closed access
Xiang HeXiang He
Xiang He
GSGengzhe Shen
Gengzhe Shen
JLJionghong Liang
Jionghong Liang
ZLZhihao Liu
Zhihao Liu
YXYue Xin
Yue Xin
XHXin He
Xin He

18 January 2023 in Biology
Verified
Journal Article
Open access
PDF file
ZLZheng Liu
Zheng Liu
JHJie He
Jie He
PJPingsong Jin
Pingsong Jin
YRYuxin Ran
Yuxin Ran
NYNanlin Yin
Nanlin Yin
HQHongbo Qi
Hongbo Qi
Preeclampsia (PE) is a pregnancy-related disorder that is a leading cause of maternal death. The failure of spiral artery remodeling due to insufficient trophoblast migration and invasion is critical in the pathogenesis of PE. Recently, the CC motif chemokine ligand 21 (CCL21) has been widely linked to cancer cell invasion and migration. However, their potential mechanisms are still unknown. In this study, we found that CCL21 expression was significantly lower in the PE group than that in the control group. In vitro experiments revealed that recombinant CCL21 could promote trophoblast cell epithelial-to-mesenchymal transitions (EMTs) and improve migration and invasion. Furthermore, an inhibitor of the ERK1/2 signaling pathway inhibited the CCL21-induced EMT process. Finally, a PE mouse model was established using the NOS inhibitor L-NAME, and we obtained similar results, with downregulated CCL21 and EMT biomarkers and upregulated CCR7. Taken together, these findings suggest that the CCL21/CCR7 axis influences EMT by activating the ERK1/2 signaling pathway, thereby affecting trophoblast cell migration and invasion, which may play a crucial role in the pathogenesis of PE.

2 December 2021 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
YMYouwen Mei
Youwen Mei
YRYuxin Ran
Yuxin Ran
ZLZheng Liu
Zheng Liu
YZYunqian Zhou
Yunqian Zhou
JHJie He
Jie He
HQHongbo Qi
Hongbo Qi

1 March 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
XFXiao ping Fan
Xiao ping Fan
JPJihai Peng
Jihai Peng
LLLiming Lei
Liming Lei
JHJie He
Jie He
JHJinsong Huang
Jinsong Huang
JCJimei Chen
Jimei Chen
Background: Progressive dilatation is responsible for significant mortality and morbidity in patients with thoracic aortic aneurysms (TAAs). Studies have shown that the development and progression of TAAs are closely related to immune regulatory pathways and genes. Therefore, it is important to understand the immune regulatory mechanisms and biomarkers of TAA dilatation. Methods: Systematic bioinformatics analysis was applied, including linear models for microarray data (LIMMA) differential expression analyses, principal component analysis (PCA), immunocyte identification, and genetic function enrichment analysis. Results: Our results showed that both aortic intima-media (AMed) and outer aortic adventitia (AAdv) tissues were closely associated with T cell activation during the process of tricuspid aortic valve (TAV)-associated TAA dilation. Additionally, the degree of infiltration of resting memory CD4+ T cells was linked to both AAdv and AMed vascular dilation. The core regulators PPTRC, IL1B, CD4, CD3G, and IL2RA were also identified and are closely related to resting memory CD4+ T cell infiltration in this pathological process. Conclusions: The candidate genes PPTRC, IL1B, CD4, CD3G, and IL2RA were involved in the regulation of resting memory CD4 T cell tissue infiltration, which is closely related to the process of AAdv and AMed vascular dilation in TAV patients.

19 December 2024 in Annals of Medicine
Verified
Journal Article
Open access
XWXiafei Wu
Xiafei Wu
JHJie He
Jie He
YBYuxiang Bai
Yuxiang Bai
YGYanqiong Gan
Yanqiong Gan
HXHongbing Xu
Hongbing Xu
XYXinyang Yu
Xinyang Yu
This study aims to investigate the risk factors for severe postpartum hemorrhage (SPPH) in patients with placenta accreta spectrum (PAS) undergoing cesarean delivery, despite the prophylactic use of resuscitative endovascular balloon occlusion of the aorta (REBOA). We conducted a retrospective case-control study on PAS patients who underwent cesarean delivery with prophylactic REBOA at the First Affiliated Hospital of Chongqing Medical University from January 2017 to December 2021. Prophylactic REBOA placement was determined by a prenatal ultrasound scoring system. Patients were divided into those who experienced SPPH (case group) and those who did not (control group), with SPPH defined by one or a combination of the following criteria: intraoperative blood loss ≥1500 mL, transfusion of ≥4 units of packed red blood cells, intraoperative hysterectomy, or sequential uterine artery embolization. Propensity score matching (PSM) was employed to minimize biases, and multivariate logistic regression was used to calculate adjusted odds ratios (aOR) for risk factors. Of the 424 enrolled patients, 102 experienced SPPH (case group), while 322 did not (control group). After PSM, the case group comprised 79 patients, and the control group included 130. After adjusting for confounders, patients with placenta increta (aOR 3, 95% CI 1.49-6.03, p = 0.002), percreta (aOR 21.77, 95% CI 6.57-72.09, p < 0.001), lower hemoglobin levels (aOR 0.98, 95% CI 0.95-1, p = 0.050), and higher D-dimer levels (aOR 1.36, 95% CI 1.12-1.65, p = 0.002) had an elevated risk of SPPH. Threshold effect analysis indicated no significant nonlinear relationship between hemoglobin, D-dimer, and outcomes. PAS patients, particularly those with placenta increta and percreta, lower hemoglobin levels, and elevated D-dimer levels, are at an increased risk of SPPH during cesarean delivery, even with REBOA intervention.